Implicit in this notion is that the activation of the RAS-MAPK pathway may be a primary oncogenic event in the tumorigenic process leading to CL1 tumors and a secondary event in the course of tumor progression in a fraction of basal-like and luminal breast cancers, eventually leading to CL2 and CL3 tumors. This evidence concerns the gene ADGRL3 and neoplasm.